echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Lancet HIV: A wide range of drug-resistant HIV strains appear, and many treatments are ineffective.

    Lancet HIV: A wide range of drug-resistant HIV strains appear, and many treatments are ineffective.

    • Last Update: 2020-09-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Acquired immunodeficiency syndrome (AIDS), or AIDS, is caused by HIV.
    an estimated 38 million people are living with HIV worldwide, and the number of AIDS-related deaths is 770,000, according to the World Health Organization.
    virus that attacks the body's immune system.
    HIV targets the body's CD4 plus T lymphocytes, weakening the body's defenses against infection and cancer.
    the emergence of drug-resistant HIV-1 has long been seen as a public health threat.
    so far, however, the probability of transmission of multidye drug-resistant strains is very low, possibly due to the reduced replication adaptability of highly mutated strains, making them less suitable for human infection than wild strains.
    meanwhile, due to the diversity of treatment drugs, multidyemic resistant strains are rarely present in HIV strains.
    previous studies have shown that less than 0.1% of primary HIV-1 infections in France are three-stage resistant.
    a recent article in THE LANCET HIV, a sub-issue of The Lancet magazine: Sexual transmission of an areadlydrug-resistant HIV-1 strain.
    reported a case of symptomatic HIV-1 primary infection confirmed in September 2019, by a 23-year-old French man who contracted the infection through sexual relations with a man.
    HIV-1 ELISA test will begin in September 2019, with incomplete immune imprinting (Fiebig IV phase), plasma HIV-1 RNA of 5.1 log10 copy/mL, and CD4 count of 821 cells/l.
    researchers used Sanger and next-generation sequencing to identify a unique, widely drug-resistant initial virus with homogeneity, a completely mutated paramilitary virus, and remained stable after treatment.
    the type B strain has drug-resistant mutations in all available nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    in addition to low levels of resistance to dolutegravir and bictegravir, there is almost complete resistance to integrated enzyme inhibitors.
    recombinant virus analysis to evaluate the use of entering co-receptors to show pure R5 physirosometers, consistent with the next generation sequencing of V3 env.
    gp41 env gene sequence shows only the Asn42Gly mutation.
    , researchers found a second widely resistant strain of HIV-1 with the same mutation pattern in a 54-year-old male in the same region of France.
    the patient has been HIV-positive since 1995 and has a long history of failed virological treatments.
    Despite the use of the treatment options for tenofowe, enqutabin, Litonave-enhanced Darunaway and Dolovewe, plasma HIV-1 RNA was still 5.5 log10 copies/mL, and CD4 count was 205 cells/l (8%).
    a quasi-species analysis of the pol and env genes through next-generation sequencing, the same significantly more resistant strains were identified, as well as variants that primarily used CCR5 and CXCR4 that used secondary.
    importantly, both patients' strains are associated with system development, but their direct transmission history cannot be determined, indicating that there are unseeded intermediate links, i.e. there is a high probability that there are other infected people! Next, the researchers plan to develop a five-drug program for patients with pure R5 gliots that will be combined with dologve (twice a day, 50 mg) for the virus's entry steps (ibalidin, Forsythave, Malawi Roque, Envweptide).
    patients with R5 and R4 mixed forms will use the same approach, but will not use Maravero.
    addition, early use of the new GS-6207 crust inhibitor may be an additional treatment option worth considering.
    the sexual transmission of this widely drug-resistant virus is unprecedented.
    2004 in New York (New York, USA) it was reported that a multi-drug-resistant strain of HIV-1 had been transmitted, but that there was no resistance to tipnavir and integrated enzyme inhibitors at the time.
    strain of HIV-1, which is widely resistant, may reduce viral adaptability.
    , however, when the source patient is transmitted to the receiving patient, the plasma virus load exceeds 5 log10 copies per milliliter, indicating that the strain is adaptable to the host.
    however, plasma viral loads tend to decrease in patients treated after primary infection, which means longer follow-up times and more research is needed on the virus adaptability of the strain.
    currently, epidemiological surveillance networks of virologists, clinicians and local preventive personnel should prevent the spread of this widely resistant HIV-1 strain.
    , new antiretroviral drugs are needed to open up alternative treatment routes for such strains.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.